What is SK bioscience?
Operating as a premier global partner in the vaccine and biopharmaceutical sector, SK bioscience specializes in the end-to-end development of preventative and curative medical solutions. The company distinguishes itself through its sophisticated, state-of-the-art manufacturing facilities, which have enabled the successful commercialization of groundbreaking products, including the world's first cell-cultured quadrivalent influenza vaccine and a domestically developed COVID-19 vaccine. By integrating high-capacity production with rigorous R&D, the firm effectively bridges the gap between laboratory discovery and global market accessibility, positioning itself as a cornerstone of modern biotechnology infrastructure.
How much funding has SK bioscience raised?
SK bioscience has raised a total of $198M across 1 funding round:
Debt
$198M
Debt (2026): $198M, investors not publicly disclosed
Key Investors in SK bioscience
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SK bioscience?
With the recent influx of capital, SK bioscience is poised to accelerate its strategic expansion and deepen its international collaborative efforts. The company is expected to prioritize the scaling of its manufacturing footprint and the diversification of its product pipeline to address emerging infectious diseases. As it navigates this phase of enterprise-level growth, the firm will likely focus on enhancing its global supply chain resilience and fostering new partnerships with international health organizations. This trajectory suggests a long-term commitment to stabilizing global health security while maintaining a competitive edge in the rapidly evolving biopharmaceutical market.
See full SK bioscience company page
